PureTech Presents Promising Preclinical Data from LYT-210 Immuno-Oncology Program at American Association for Cancer Research...
12 April 2021 - 9:00PM
Business Wire
Novel antibody demonstrates highly specific and
highly potent targeting of immunosuppressive γδ1 T cells from
cancer patients
Enriched in many intractable solid tumors and
blood of cancer patients, γδ1 T cells represent important new
target for cancer immunotherapy
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the
“Company”), a clinical-stage biotherapeutics company dedicated to
discovering, developing and commercializing highly differentiated
medicines for devastating diseases, today announced the
presentation of a scientific poster detailing additional promising
preclinical results for its LYT-210 antibody at the 2021 American
Association for Cancer Research (AACR) Annual Virtual Meeting.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210412005194/en/
PureTech announced the presentation of a
scientific poster detailing additional promising preclinical
results for its LYT-210 antibody at the 2021 AACR Annual Virtual
Meeting. The new research demonstrates that LYT-210 is both highly
specific and highly potent, rapidly inducing cell death of
immune-suppressive gamma delta-1 T cells, while sparing other T
cells that play important roles in a healthy immune response.
(Photo: Business Wire)
LYT-210 is a novel, fully human monoclonal antibody (mAb)
directed against T cells bearing γδ1 receptors, which are known to
suppress the anti-tumor immune response. The new research shared at
AACR demonstrates that LYT-210 is both highly specific and highly
potent, rapidly inducing cell death of immune-suppressive γδ1 T
cells, while sparing other T cells that play important roles in a
healthy immune response. The research was conducted in vitro using
both patient blood and cancer tissue. LYT-210 has potential as
either a single agent or in combination with checkpoint inhibitors
and other anti-cancer treatments.
“The role of γδ1 T cells in cancer immune suppression has come
into sharp focus in recent years. We now know that these cells
deploy multiple immunosuppressive signals to dampen the anti-tumor
response and enable the cancer to grow and spread,” said Aleksandra
Filipovic, M.D. Ph.D., Head of Oncology at PureTech. “We are
excited by these new data demonstrating that our LYT-210
therapeutic candidate can precisely target and swiftly deplete
pathogenic γδ1 T cells. We believe that removing these culprits
from the tumor microenvironment systemically may have the potential
to reawaken the immune system and contribute to a strong anti-tumor
response. Moreover, both we and others in the field have
established that a heightened presence of pathogenic γδ1 T cells in
tumor tissue and blood is correlated with more aggressive disease,
poorer response to some therapies and a lower chance of survival.
Given those links, we believe that the biomarker-centric approach
we are developing as part of our γδ1 T cell program may have the
potential to identify and select the patients who are most likely
to benefit from LYT-210 in the clinic and beyond.”
γδ1 T cells are upregulated in multiple solid tumors including
breast cancer, glioblastoma, melanoma and pancreatic cancer. They
suppress the immune response through multiple mechanisms, including
blocking effector T cells, hindering antigen-presenting dendritic
cells, restricting the anti-tumoral activity of γδ2 T cells and
attracting tumor-associated macrophages and myeloid-derived
suppressor cells to the tumor microenvironment. Pathogenic γδ1 T
cells are distinct from cytotoxic γδ T cells, which are being used
for adoptive T cell transfer or therapeutic engagement with
bispecific antibodies. Depleting pathogenic γδ1 T cells has the
capacity to modulate both innate and adaptive immunity, and their
distinct phenotypic and functional properties make them excellent
potential therapeutic targets.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech’s Founded Entities,
as of the date of PureTech’s most recently filed Registration
Statement on Form 20-F, was comprised of 24 therapeutics and
therapeutic candidates, including two that have received FDA
clearance and European marketing authorization. All of the
underlying programs and platforms that resulted in this pipeline of
product candidates were initially identified or discovered and then
advanced by the PureTech team through key validation points based
on the Company’s unique insights into the biology of the brain,
immune and gut, or BIG, systems and the interface between those
systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, our expectations regarding the potential therapeutic benefits
of our therapeutic candidates, our expectations regarding the
potential mechanism of action and related benefits expected from
LYT-210 based on the preclinical results presented at AACR, and
those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210412005194/en/
Investors Allison Mead Talbot +1 617 651 3156
amt@puretechhealth.com
U.S. media Stephanie Simon +1 617 581 9333
stephanie@tenbridgecommunications.com
PureTech Health (NASDAQ:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
PureTech Health (NASDAQ:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024